Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Conclusion: These findings demonstrate the feasibility of using organ dose for a phase 1 escalation design and suggest the safety of using 90Y-DOTATOC and 131I-MIBG.

Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Bushnell, D. L., Bodeker, K. L., ODorisio, T. M., Madsen, M. T., Menda, Y., Graves, S., Zamba, G. K. D., ODorisio, M. S. Tags: Clinical Source Type: research